Global Congress on Bladder Cancer 2018

Upper Tract Urothelial Carcinoma - Adjuvant Chemotherapy for all Patients?

Madrid, Spain (UroToday.com) Alison Birtle, MD gave an overview of the current data on upper tract urothelial carcinoma (UTUC) with data on adjuvant and neoadjuvant chemotherapy, and the summarized results of the phase III POUT trial.

Perioperative Chemotherapy in Cisplatin “Unfit” Patients

Madrid, Spain (UroToday.com) Dr. Maria De Santis gave a talk on the large subset of cisplatin “unfit” patients. Of all patients with muscle-invasive bladder cancer (MIBC) only ~50% will be alive five years after diagnosis. Relapse mostly occurs with distant metastasis – but the disease is always a systemic one. Cisplatin-based chemotherapy and immunotherapy are active and have shown to improve survival. Cystectomy is the preferred definitive treatment in many parts of the world. Neoadjuvant chemotherapy is indicated in patients with clinical stage T2-T4 N0 M0. Induction chemotherapy is indicated in positive node disease but with localized MIBC.

Controlling Symptoms in Metastatic Bladder Cancer

Madrid, Spain (UroToday.com) Dr. Bracarda gave some highlights and some important points on how to control symptoms in metastatic bladder cancer patients. Dr. Bracarda began his talk with some epidemiologic data, showing that there is an increase in the median age and number of comorbidities of patients with bladder cancer. Worldwide, urothelial bladder cancer is the 7^th most common cancer in men and 17^th in women. About 70% of cases present with non-muscle invasive bladder cancer (NMIBC). There are different incidence rates between men and women, frequently attributed to different historical smoking patterns. Hormonal differences and their effect on the epidemiology of this disease is currently not known.

Saving Bladders with Brachytherapy Using Robot-Assisted Laparoscopically Performed Implantations for Solitary Muscle-Invasive Bladder Tumors

Madrid, Spain (UroToday.com) This poster presentation was one of three posters that won an award for best poster and was therefore presented on a podium. Dr. Steen, a urologist, and Dr. van-der Steen-Banasik, a radiation oncologist from the Netherlands presented their study together.

VISTA, Phase 3 Trial of Vicinium™, an EPCAM-Targeted Pseudomonas Exotoxin, in BCG – Unresponsive Non-Muscle Invasive Bladder Cancer

Madrid, Spain (UroToday.com) This poster presentation was one of three posters that won an award for best poster and was therefore presented on a podium. Dr. Adams, an immunologist from Sesen Bio, gave some background on Vicinium™, which is a novel fusion protein designed to increase tumor targeting and drug safety.

BCG vs Chemohyperthermia with Mitomycin C for High-Risk Non-Muscle Invasive Bladder Carcinoma: Preliminary Results of HIVEC-HR Randomized Clinical Trial

Madrid, Spain (UroToday.com) The shortage of Bacillus Calmette–Guérin (BCG) intravesical instillations that occurred several years ago resulted in the expedited search for alternative therapeutic options for a patient with non-muscle invasive bladder cancer (NMIBC).

Bladder Cancer in the "Golden Years"

Madrid, Spain (UroToday.com) The mean age of bladder cancer diagnosis is 73 years, with a life expectancy of 79.2 in British men and 82.9 in females. Treating elderly patients with bladder cancer remains a challenge, as they represent a unique cohort of patients; harboring a myriad of co-morbidities, with different desires and thoughts, which at times differ substantially from those of younger patients.

Page 1 of 4

Global Congress on Bladder Cancer 2018

Free Daily and Weekly newsletters offered by content of interest

Login